| Literature DB >> 33280397 |
Calvo Trujillo Susana1, Toribio Martín Luisa Maria2, Domenech Senra Pilar3, Mingo Moreno Teresa María4, Marín Solano Pilar5, Martín González Valentín6.
Abstract
BACKGROUND: Cervical pain is a problem with a high prevalence of ~13% of the population, and is more common in women (16.5%). The most affected age group is 65-74 years. Our aim was to assess the effectiveness of self-applied acupressure for decreasing benign-origin cervical pain, under the supervision of a health professional and in combination with usual treatment, as well as to examine its impact on the patient's self-perceived health condition and their opinion of the technique.Entities:
Keywords: acupressure; musculoskeletal disorders; orthopaedics & trauma; pain management
Mesh:
Year: 2020 PMID: 33280397 PMCID: PMC8442130 DOI: 10.1177/0964528420961398
Source DB: PubMed Journal: Acupunct Med ISSN: 0964-5284 Impact factor: 2.267
Figure 1.Flowchart of patients and losses to follow-up between baseline visit (V1) and subsequent visits at 3 days (V2), 7 days (V3), 30 days (V4), and 90 days (V5).
Comparative analysis of socio-demographic variables and baseline data.
| Total | Control | Intervention | p value | |
|---|---|---|---|---|
| Sex, n (%) | 150 | 73 | 77 | 0.543 |
| Female | 130 (86.7) | 62 (84.9) | 68 (88.3) | |
| Male | 20 (13.3) | 11 (15.0) | 9 (11.7) | |
| Age, mean (SD) | 150 | 73 | 77 | 0.316 |
| 45 (10.6) | 45.9 (10.6) | 44.1 (10.5) | ||
| Educational level, n (%) | 145 | 69 | 76 | 0.446 |
| Primary education | 46 (31.7) | 19 (27.5) | 27 (35.5) | |
| Secondary education, vocational training, and others | 72 (49.7) | 38 (55.0) | 34 (44.8) | |
| College and university education | 27 (18.6) | 12 (17.4) | 15 (19.8) | |
| Employment situation, n (%) | 145 | 69 | 76 | 0.803 |
| Unemployed/retired | 20 (13.8) | 9 (13.0) | 11 (14.4) | |
| Active worker | 125 (86.2) | 60 (86.9) | 65 (85.5) | |
| Physical exercise more than once a week, n (%) | 145 | 69 | 76 | 0.500 |
| No | 84 (57.9) | 39 (55.0) | 40 (60.5) | |
| Yes | 61 (42.0) | 31 (44.9) | 30 (39.5) | |
| Previous record of related neck pathology | 145 | 69 | 76 | |
| Scoliosis (no) | 132 (91.0) | 63 (91.3) | 69 (91.0) | 0.914 |
| Head and/or neck trauma (no) | 130 (89.7) | 60 (87.0) | 70 (92.1) | 0.309 |
| Chronic pathology | 145 | 69 | 76 | 0.777 |
| No | 90 (62.0) | 42 (62.9) | 48 (63.1) | |
| Yes | 55 (37.4) | 27 (39.1) | 28 (36.8) | |
| Days suffering pain (SD) | 145 | 69 | 76 | 0.436 |
| 32.9 (34.5) | 35.2 (35.8) | 30.8 (33.3) | ||
| Days of work leave with pain (SD) | 145 | 69 | 76 | 0.669 |
| 2.8 (8.0) | 2.5 (8.3) | 3.0 (7.8) | ||
| Functional capability with pain | 150 | 73 | 77 | 0.104 |
| ⩽30% | 18 (12.0) | 10 (13.7) | 8 (10.4) | |
| 40%–50% | 38 (25.3) | 12 (16.4) | 26 (33.8) | |
| 60%–70% | 36 (24.0) | 20 (27.4) | 16 (20.8) | |
| 80%–90% | 45 (30.0) | 22 (30.1) | 23 (29.9) | |
| 100% | 13 (8.7) | 9 (12.3) | 4 (5.2) | |
| Previous diagnostic tests | 144 | 69 | 75 | 0.617 |
| 41 (28.5) | 21 (30.4) | 20 (26.7) | ||
| Previous evaluation by specialized care (yes) | 150 | 0.715 | ||
| 27 (18.0) | 14 (19.2) | 13 (16.9) | ||
| Previous pharmacological treatment | 145 | 69 | 76 | 0.934 |
| Yes | 116 (80.0) | 55 (79.9) | 61 (80.3) | |
| No | 29 (20.0) | 14 (20.3) | 15 (19.7) | |
| Type of previous pharmacological treatment | 145 | 69 | 76 | |
| NSAIDs | 92 (63.4) | 43 (62.3) | 49 (64.5) | 0.788 |
| Non-NSAID analgesics | 43 (29.7) | 23 (33.3) | 20 (26.3) | 0.355 |
| Muscle relaxant | 6 (4.1) | 2 (2.9) | 4 (45.3) | 0.475 |
| Diazepam | 38 (26.2) | 19 (27.4) | 19 (27.4) | 0.729 |
| Location of pain | 144 | 69 | 75 | 0.023 |
| Neck | 23 (16.0) | 16 (23.2) | 7 (9.3) | |
| Neck and shoulders | 121 (84.0) | 53 (76.9) | 68 (90.7) | |
| Type of cervical pain | 144 | 69 | 75 | 0.221 |
| Acute <6 weeks | 52 (36.1) | 23 (33.3) | 29 (38.7) | |
| Sub-acute >6 weeks | 27 (18.7) | 17 (24.6) | 10 (13.1) | |
| Chronic >6 months | 65 (45.1) | 29 (42.0) | 36 (48.0) | |
| VAS, cm (SD) | 144 | 69 | 75 | 0.963 |
| 6.5 (1.7) | 6.5 (1.6) | 6.5 (1.7) |
SD: standard deviation; NSAIDs: non-steroidal anti-inflammatory drugs; VAS: visual analogue scale.
Intervention effectiveness at 1, 3, 7, 30, and 90 days.
| Visit 1: basal (n = 147) | Visit 2: day 3 (n = 138) | Visit 3: day 7 (n = 135) | Visit 4: day 30 (n = 125) | Visit 5: day 90 (n = 94) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| p | p | p | p | p | |||||||
| Pain VAS | Intervention | 6.5 (6.10 to 6.90) | 0.980 | 4.5 (3.98 to 5.05) | 0.205 | 3.9 (3.36 to 4.58) | 0.917 | 3.3 (2.68 to 4.07) | 0.396 | 2.2 (1.52 to 2.98) | <0.01 |
| Control | 6.5 (6.12 to 6.90) | 5.0 (4.47 to 5.53) | 4.0 (3.44 to 4.60) | 3.8 (3.06 to 4.55) | 3.8 (3.05 to 4.71) | ||||||
| p | p | p | p | p | |||||||
| Utilities EuroQol-5D | Intervention | 0.6 (0.41 to 0.74) | 0.592 | 0.7 (0.63 to 0.79) | 0.592 | 0.7 (0.63 to 0.79) | 0.156 | 0.8 (0.71 to 1.00) | <0.01 | 0.8 (0.74 to 1.00) | <0.01 |
| Control | 0.6 (0.38 to 0.74) | 0.7 (0.63 to 0.79) | 0.7 (0.68 to 0.79) | 0.7 (0.63 to 0.79) | 0.7 (0.65 to 0.79) | ||||||
| % (CI 95%) | p | % (CI 95%) | p | % (CI 95%) | p | % (CI 95%) | p | % (CI 95%) | p | ||
| Prescribed analgesia | Intervention | 76.0 (66.3 to 85.7) | <0.01 | 62.5 (51.3 to 73.7) | 0.037 | 57.5 (46.2 to 68.9) | 0.177 | 37.3 (25.7 to 48.9) | 0.023 | 27.3 (15.5 to 39.0) | 0.055 |
| Control | 94.2 (88.7 to 99.7) | 78.8 (68.9-88.7) | 68.9 (57.2 to 80.5) | 57.6 (45.0 to 70.2) | 45.7 (31.3 to 60.0) | ||||||
| % (CI 95%) | p | % (CI 95%) | p | % (CI 95%) | p | % (CI 95%) | p | % (CI 95%) | p | ||
| TD | Intervention | 14.3 (6.5 to 22.1) | 0.135 | 13.0 (5.5 to 20.5) | 0.0473 | 9.1 (2.7 to 15.5) | 0.393 | 4.11 (−0.4 to 8.7) | 0.999 | 1.3 (−1.2 to 3.8) | 0.970 |
| Control | 6.9 (1.1 to 12.6) | 4.1 (−0.1 to 8.7) | 5.5 (0.0 to 10.7) | 0.0 (0.0 to 0.0) | 1.4 (−1.3 to 4.0) | ||||||
| p | p | p | p | p | |||||||
| NDI | Intervention | 26.0 (21.0 to 32.0) | 0.024 | 20.0 (16.0 to 25.0) | 0.780 | 19.0 (15.0 to 23.0) | 0.343 | 16.0 (12.0 to 22.0) | 0.381 | 14.5 (10.5 to 20.5) | 0.217 |
| Control | 23.0 (18.0 to 27.0) | 20.0 (15.5 to 24.0) | 16.0 (14.0 to 22.0) | 17 (13.0 to 23.0) | 17.5 (12.0 to 21.0) | ||||||
TD: temporary disability; NDI: neck disability index; VAS: visual analogue scale; IQM: interquartile mean.
Explanative generalizing estimating equation model of the effectiveness of acupressure for quality of life utilities, functional capability, and pain scores.
| Utilities (EuroQol-5D) | Pain VAS | |||||
|---|---|---|---|---|---|---|
| Coefficient | p > z | 95% CI | Coefficient | p > z | 95% CI | |
| Intervention | 0.049 | 0.031 | 0.004 to 0.0944 | −0.157 | 0.69 | −0.797 to 0.48 |
| Visit 1 (baseline) | 0.0007 | 0.036 | 0.00004 to 0.001 | −0.013 | 0.005 | −0.022 to −0.003 |
| Difference between visits V1–V5 | 0.001 | 0.037 | 0.00005 to 0.0019 | −0.016 | 0.008 | −0.02 to −0.004 |
| Functional capability at visit 1 (baseline) | ||||||
| 40%–50% | −0.052 | 0.151 | −0.123 to 0.019 | 0.604 | 0.254 | −0.434 to 1.644 |
| 60%–70% | −0.025 | 0.485 | −0.097 to 0.046 | 0.444 | 0.404 | −0.598 to 1.48 |
| 80%–90% | −0.039 | 0.266 | −0.1090 to 0.030 | 0.398 | 0.438 | −0.607 to 1.404 |
| 100% | −0.034 | 0.439 | −0.121 to 0.052 | 1.371 | 0.033 | 0.11 to 2.63 |
| NDI at visit 1 (baseline) | ||||||
| Moderate disability | −0.08 | 0.062 | −0.164 to 0.003 | 0.452 | 0.466 | −0.164 to 0.003 |
| Severe disability | −0.16 | 0 | −0.24 to −0.075 | 1.391 | 0.026 | −0.24 to −0.075 |
| Complete disability | −0.279 | 0 | −0.38 to −0.173 | 1.326 | 0.088 | −0.38 to −0.173 |
| Chronic disability | 0.806 | 0 | 0.699 to 0.91 | 3.861 | 0 | 2.328 to 5.395 |
| n = 614 | n = 614 | |||||
V: visit; NDI: neck disability index; VAS: visual analogue scale; CI: confidence interval.
Adverse effects in 74 patients and number of related dropouts at each visit.
| Visit 2 | Visit 3 | Visit 4 | Visit 5 | Total | |
|---|---|---|---|---|---|
| Dizziness | 8/0 | 10/0 | 5/0 | 4/0 | 27/0 |
| Hypotension | 1/0 | 2/0 | 1/0 | 0/0 | 4/0 |
| Hematoma | 1/0 | 0/0 | 0/0 | 0/0 | 1/0 |
| Pain | 16/0 | 14/0 | 10/0 | 4/0 | 44/0 |
| Does not know | 1/0 | 1/0 | 0/0 | 2/1 | 4/1 |
| Total | 27/0 | 27/0 | 16/0 | 10/1 | 80/1 |
Figure 2.Evolution of pain in both groups measured on a visual analogue scale (VAS) at baseline visit (V1) and follow-up visits at 3 days (V2), 7 days (V3), 30 days (V4), and 90 days (V5).